BioTrends Research Group releases Wave One LaunchTrends: EXTAVIA report

BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends(®): EXTAVIA report. The survey was completed by U.S. Neurologists Extavia (Interferon beta 1b).

Awareness of Extavia is relatively high but familiarity is more moderate. Over one-third of current Extavia users indicate this newest agent will be a likely replacement for Betaseron (interferon beta-1b) manufactured by Bayer, which was the first disease modifying agent approved nearly 20 years ago. Despite the relatively high awareness of Extavia, the projected uptake of Extavia appears to be modest with about half of the Neurologists expecting to prescribe Extavia within the next six months. The main advantages clinicians perceive with Extavia is the every other day dosing regimen and similarity to other interferon agents. On the downside, Extavia is viewed as yet another addition to an already crowded market with a similar mechanism of action and a lack of any clear clinical differentiation. According to one research participant, "Extavia is overshadowed by other new products. It's hard to get a real sense of excitement." Concern was also expressed that the treatment may not be priced sufficiently less expensive than existing agents to encourage its use, despite the fact that the pricing advantage was one of the most frequently recalled sales representative messages about the product.

Currently approved products include Biogen Idec's AVONEX and TYSABRI; Teva's COPAXONE and EMD Serono's REBIF. In an attribute analysis, surveyed Neurologists rated Copaxone as the top performing agent on nine out of ten of the most important attributes. There are also a number of agents in late stage clinical development for MS. There is a high degree of interest in the oral agents currently in development among which interest was highest for Novartis' own fingolimod, an oral sphingosine-1 modulator and EMD Serono's oral cladribine. EMD Serono received a refuse to file letter from the FDA dated November 30(th) and is currently working with the FDA toward a possible resubmission.

LaunchTrends (®) measure launch effectiveness of new products from FDA approval through six months post launch. The next wave of this report, measuring uptake at three months post launch, will be fielded on February 15th with the results to be published on February 28, 2010.

As part of BioTrends continuing commitment to the MS market we are pleased to announce the continuation of the TreatmentTrends(®): Multiple Sclerosis Report in 2010. This second report in an on-going series will cover U.S. market trends including key product use (current and future) across the different clinical manifestations of MS, disease awareness and attitudes, importance of product attributes for disease modifying therapies and brand performance against those attributes, and awareness of products in late stage development. This report is scheduled to field at the end of January and will be published in mid-February.

SOURCE BioTrends Research Group, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Compact rapid detection kit to test for monkeypox virus shows promising results in new research